Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > (-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine

(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine

(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine structure

(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine 

structure
  • CAS No:

    300543-56-0

  • Formula:

    C17H19ClN2

  • Chemical Name:

    (-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine

  • Synonyms:

    Piperazine,1-[(R)-(4-chlorophenyl)phenylmethyl]-;1-[(R)-(4-Chlorophenyl)phenylmethyl]piperazine;(R)-1-(p-Chlorobenzhydryl)piperazine;(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine;N-[(R)-α-(4-Chlorophenylbenzyl]piperazine;1-[(R)-α-(4-Chlorophenylbenzyl]piperazine;1-[(R)-(4-Chlorophenyl)-phenylmethyl]piperazine;(R)-1-((4-Chlorophenyl)(phenyl)methyl)piperazine;130018-88-1

  • Categories:

    Pharmaceutical Intermediates  >  Heterocyclic Compound

(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine Basic Attributes

286.8

286.80

1312995-182-4

890A9G29PG

2933599090

Characteristics

15.3

3.4

White Solid

1.2±0.1 g/cm3

409.1°C at 760 mmHg

193.3±26.5 °C

1.592

soluble in chloroform, methanol, and dichloromethane. Slightly soluble in water.

6.66E-07mmHg at 25°C

Safety Information

NONH for all modes of transport

|Warning|H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P391, P403+P233, P405, and P501|Aggregated GHS information provided by 4 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine Use and Manufacturing

Methods of Manufacturing

40.0 g of 1-[(R)-(4-chlorophenyl) (phenyl) methyl] piperazine, 14.1 g of sodium hydrogen carbonateAnd a mixture of 78.1 g of N-methyl-2-pyrrolidoneHeat to 120 C, ethyl (2-chloroethoxy) acetateAfter 27.9 g was dropped over 30 minutes, the mixture was stirred for 6 hours.After cooling the obtained suspension to room temperature, 200 g of waterAnd toluene 69gAnd the mixture was separated.120 g of water is added to the obtained organic layer, and liquid separation is performed again to obtain the formula (6).; 32 g of water was added to a toluene solution of the compound (6) obtained in Reference Example 1, and a solution of 7.0 g of lithium hydroxide monohydrate dissolved in 44 g of water was added dropwise at room temperature. It stirred until it became 0.2% or less. Liquid separation was carried out after the obtained solution, 8 g of N-methyl-2-pyrrolidone for washing, 139 g of toluene and 25 g of acetone were mixed. To the separated aqueous layer were added 139 g of toluene and 13 g of acetone to carry out liquid separation again. Further, 139 g of toluene and 9 g of acetone were added to the separated aqueous layer, and liquid separation was performed again. 35 g of toluene and 193 g of methyl ethyl ketone were added to the obtained aqueous layer, and 29.1 g of 35% hydrochloric acid was dropped to adjust the pH to 2.4, and the solution was heated to 45 C. to separate. After 35 g of toluene was added to the obtained organic layer, concentration was performed until the remaining amount became 95 g. Furthermore, 97 g of methyl ethyl ketone and 35 g of toluene were added and concentrated until the remaining amount reached 99 g, and further 24 g of methyl ethyl ketone and 9 g of toluene were added and concentrated until the remaining amount became 101 g. After adding methyl ethyl ketone 64g and acetone 411g at room temperature and dropping 7.3g of 35% hydrochloric acid, 0.04 g of levocetirizine dihydrochloride was added.Subsequently, 316 g of acetone was dropped, and after stirring for 1.5 hours, 6.9 g of 35% hydrochloric acid was dropped. After filtering the obtained suspension, the obtained solid was washed with 95 g of acetone. The obtained crystals were dried under reduced pressure at 40 C. to obtain 54.6 g of levocetirizine dihydrochloride. The purity was 99.8% or more

Uses

Intermediate in the production of (R)-Cetirizine (C281106).

Computed Properties

Molecular Weight:286.8
XLogP3:3.4
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:3
Exact Mass:286.1236763
Monoisotopic Mass:286.1236763
Topological Polar Surface Area:15.3
Heavy Atom Count:20
Complexity:277
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of (-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.